[{"orgOrder":0,"company":"Orsenix","sponsor":"Syros Pharmaceuticals","pharmaFlowCategory":"D","amount":"$28.0 million","upfrontCash":"$12.0 million","newsHeadline":"Syros Acquires Clinical-Stage Drug Candidate from Orsenix for Acute Promyelocytic Leukemia","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Medsenic Partners With Phebra for the Clinical Development of the Oral Form of Arscimed\u00ae for the Treatment of Autoimmune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Australasian Leukaemia and Lymphoma Group","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Final Results of Bioavailability Study of Phebra's Oral Arsenic Capsule for APL Confirm Bioequivalence of Oral and IV Formulations","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"","productType":"Small molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Notice of Approval for a New US Patent Broadening the Use of Arsenic Trioxide to Treat the Relapsing-Remitting Form of Multiple Sclerosis","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Bone Therapeutics","sponsor":"Medsenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Bone Therapeutics to Start a New Euronext Equity Story with A Change of Name to Bio Senic, Following the Acquisition of A Majority Participation of Medsenic Valued at EUR 40 Million","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"October 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"National Cancer Institute","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Drug Combination Helps Children with Acute Promyelocytic Leukemia Avoid Conventional Chemotherapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Preclinical","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Preclinical"},{"orgOrder":0,"company":"Medsenic","sponsor":"Phebra","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Biosenic Provides Update Regarding Current License Agreement With Phebra","therapeuticArea":"Immunology","highestDevelopmentStatus":"N\/A","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"May 2023","url1":"","url2":"","graph1":"Immunology","graph2":"N\/A"},{"orgOrder":0,"company":"BioSenic","sponsor":"ABO Securities","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Signs a New Subscription Agreement for a Maximum of EUR 1.2M in Convertible Bonds","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Phebra","sponsor":"BioSenic","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Reaches Agreement on a Binding Term Sheet with Phebra PTY Ltd. with Respect to the Development of the First Oral Formulation of Arsenic Troxide for cGvHD Treatment","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"AUSTRALIA","productType":"Small molecule","productStatus":"Approved","date":"January 2024","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"BioSenic","sponsor":"Gestys Sant\u00e9 Biotech","pharmaFlowCategory":"D","amount":"$0.5 million","upfrontCash":"Undisclosed","newsHeadline":"BioSenic Raises \u20ac500,000 in Private Placement of New Shares with Established New Investors","therapeuticArea":"Immunology","highestDevelopmentStatus":"IND Enabling","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Immunology","graph2":"IND Enabling"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Receives Positive Pre-IND Response from FDA to Initiate a Phase III Clinical Study in cGvHD","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"June 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Medsenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Medsenic Publishes an Article in Transplantation and Cellular Therapy, Unveiling High Response Rate and Corticosteroid Sparing With Arsenic Trioxide-based First-line Therapy in cGvHD after allo-HSCT","therapeuticArea":"Immunology","highestDevelopmentStatus":"Preclinical","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"July 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Preclinical"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic SA Provides Update On Its Autoimmune Disease Platform Based On ATO (arsenic trioxide)","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"November 2022","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"BioSenic Receives Key European Patent From EPO, For Further Therapeutic Development in Cancer, Infectious and Immune Diseases","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"April 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"BioSenic","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Biosenic Performs Further Analysis of its Phase 2 Clinical Trial Data, Leading to an Optimal Administration Scheme for its Next Late-Stage Trial of Arsenic Trioxide In Cgvhd","therapeuticArea":"Immunology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"BELGIUM","productType":"Small molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Immunology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals for Arsenic Trioxide
BioSenic intends to use the net proceeds to prepare for an IND application with FDA for the Phase 3 clinical study with Arscimed, an oral arsenic trioxide (OATO) in the first-line treatment of chronic graft-versus-host disease (cGvHD).
The agreement aims for the development of the first oral formulation of ArsciCor (arsenic troxide) in the field of several targeted autoimmune diseases, including for cGvHD treatment.
The proceeds of the financing will essentially contribute to continuing to advance the clinical development of BioSenic’s lead asset, its ATO product, Arscimed (arsenic trioxide), in the treatment of chronic graft versus host disease (cGvHD).
ATO (arsenic trioxide) is administered daily by IV infusions, which is investigated for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious disease.
Under the license agreement, Medsenic agreed to commence a clinical study using Phebra's oral formulation OATO (arsenic trioxide) for the treatment of Graft Versus Host Disease, Systemic Sclerosis, Systemic Lupus Erythematosus and infectious diseases.
Arscimed® (arsenic trioxide), is a able to radically modify the autoimmune cascade and normalise the immune system without causing nonspecific immunosuppressionbeing studied for cGvHD.
The BioSenic autoimmune platform has been constructed to target systemic autoimmune diseases using arsenic trioxide (Arscimed, ATO). This uses ATO’s first-in-class mechanism of action as an active anti-inflammatory and immunomodulatory agent.
The acquisition of Medsenic and its specialized pipeline in the development of optimized formulations of arsenic trioxide (Arscimed) and their applications in serious inflammatory/autoimmune conditions and other potential new indications.
First-line combination of Arscimed (arsenic trioxide) and prednisone in cGvHD showed an Overall Response Rate (ORR) at 6 months of 75%, allowing rapid corticosteroid tapering.
The primary endpoint of this prospective, multicenter, non-randomized study was the improvement of treatment response with Arscimed® (arsenic trioxide) in combination with prednisone, with or without cyclosporine.
Market Place
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
